Pharmafile Logo

Parsabiv

- PMLiVE

Amgen set for Kyprolis label boost after CHMP backing

Multiple myeloma treatment set to add new survival data

- PMLiVE

NICE backs trial of online and mobile depression programme

First digital psychological therapy briefing covers Servier and Gaia's Deprexis

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

Biogen Idec building

NICE finally starts review of Biogen’s Spinraza for SMA

Will evaluate the treatment based on its Single Technology Appraisal process

- PMLiVE

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment

- PMLiVE

NICE backs GSK’s €594k gene therapy for rare disease

The treatment offers 'bubble baby' patients an alternative to a stem cell transplant

National Institute for Health and Care Excellence NICE logo

NICE to look again at Pfizer’s Besponsa after appeal

The blood cancer medicine was originally turned down on cost-effectiveness grounds

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

- PMLiVE

Amgen gets prevention claim for cholesterol drug Repatha

FDA approves new labelling on heart attack and stroke risk reduction

- PMLiVE

NICE set to reject wider use of Eisai’s Halaven

Issues draft guidance recommending against second-line use in breast cancer

- PMLiVE

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

National Institute for Health and Care Excellence NICE logo

NICE backs two advanced breast cancer drugs after price cuts

An estimated 8,000 women will be eligible to receive the drugs due to discounts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links